Condition: Advanced Solid Tumor · Sponsor: OBI Pharma, Inc
This is a 3-part study. Phase 1a (dose escalation) is designed to assess the safety and tolerability and to determine the maximum tolerated dose (MTD) and putative recommended phase 2 dose (RP2D) of study drug as monotherapy. Phase 1b (Cohort Expansion) is intended to further characterize the safety and preliminary antitumor activity of the putative RP2D of OBI-902 in selected tumor types. Phase 2 (Randomized Dose Optimization Cohorts) is intended to determine the optimal RP2D of OBI-902 in selected tumor types, before advancing to larger Phase 3 trials.
This description comes directly from the study's public registry record.
OBI Pharma, Inc. Sponsor · 1-619-537-7821 · clinicaltrials.gov-queries@obipharma.com
Always discuss trial participation with your own doctor first.
| Scripps Green Hospital | La Jolla, California, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
| Wan Fan Hospital | Taipei, Wenshan, Taiwan | Recruiting |
| Shuang Ho Hospital | Taipei, Zhonghe, Taiwan | Active Not Recruiting |
| China Medical University Hospital | Taichung, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07124117